Q-omics provides the consensus-scored SNX19P2 profile across patient tissues and cancer cell-line models. SNX19P2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SNX19P2 is differentially expressed in 5, with the highest sampling consensus in THCA. Additionally, SNX19P2 RNA expression shows 16,428 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, THCA, and THYM as cancer lineages where SNX19P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SNX19P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SNX19P2 survival associations across molecular data types. SNX19P2 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SNX19P2 RNA expression–survival associations across cancer types. High SNX19P2 expression shows unfavorable associations in HNSC, UCEC and MESO, but favorable associations in KIRC, UCS and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify KIRC as the clearest survival context for SNX19P2 RNA expression.
This table summarizes SNX19P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SNX19P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SNX19P2 shows lower tumor expression in THCA, KIRC, READ and UCEC and higher tumor expression in LUAD. The THCA box plot shows higher SNX19P2 RNA expression in normal versus tumor tissue (log2 FC = −0.075, t-test p = .003).
This table shows molecular features associated with SNX19P2 in patient tissues and cancer cell lines. In patient samples, SNX19P2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
